These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 39278918)

  • 1. Sintilimab combined with anlotinib and chemotherapy as second-line or later therapy in extensive-stage small cell lung cancer: a phase II clinical trial.
    Han X; Guo J; Li L; Huang Y; Meng X; Wang L; Zhu H; Meng X; Shao Q; Li X; Zhang Y; Wang J; Chen Y; Zhang Y; Chen Y; Zhu C; Wang Z
    Signal Transduct Target Ther; 2024 Sep; 9(1):241. PubMed ID: 39278918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of ICI plus anlotinib vs. anlotinib alone as third-line treatment in extensive-stage small cell lung cancer: a retrospective study.
    Chen Q; Li Y; Zhang W; Wang C; Yang S; Guo Q
    J Cancer Res Clin Oncol; 2022 Feb; 148(2):401-408. PubMed ID: 34797416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anlotinib plus etoposide and cisplatin/carboplatin as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): a single-arm, phase II study.
    Kong T; Chen L; Zhao X; Duan F; Zhou H; Wang L; Liu D
    Invest New Drugs; 2022 Oct; 40(5):1095-1105. PubMed ID: 35788937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety analysis of anlotinib in combination with immune checkpoint inhibitors for second-line and subsequent extensive-stage small-cell lung cancer.
    Ying X; Shi Z; Shao R; You G; Song Z
    Neoplasma; 2024 Jun; 71(3):297-305. PubMed ID: 38958712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trial.
    Cheng Y; Chen J; Zhang W; Xie C; Hu Q; Zhou N; Huang C; Wei S; Sun H; Li X; Yu Y; Lai J; Yang H; Fang H; Chen H; Zhang P; Gu K; Wang Q; Shi J; Yi T; Xu X; Ye X; Wang D; Xie C; Liu C; Zheng Y; Lin D; Zhuang W; Lu P; Yu G; Li J; Gu Y; Li B; Wu R; Jiang O; Wang Z; Wu G; Lin H; Zhong D; Xu Y; Shu Y; Wu D; Chen X; Wang J; Wang M; Yang R
    Nat Med; 2024 Oct; 30(10):2967-2976. PubMed ID: 38992123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anlotinib plus oral fluoropyrimidine S-1 in refractory or relapsed small-cell lung cancer (SALTER TRIAL): a multicenter, single-arm, phase II trial.
    Wang W; Wu G; Luo W; Lin L; Zhou C; Yao G; Chen M; Wu X; Chen Z; Ye J; Yang H; Lv D
    BMC Cancer; 2024 Sep; 24(1):1182. PubMed ID: 39333988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response to first-line treatment predicts progression-free survival benefit of small-cell lung cancer patients treated with anlotinib.
    Qin B; Xin L; Hou Q; Yang B; Zhang J; Qi X; Wei Y; Hu Y; Xiong Q
    Cancer Med; 2021 Jun; 10(12):3896-3904. PubMed ID: 33960145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-line penpulimab (an anti-PD1 antibody) and anlotinib (an angiogenesis inhibitor) with nab-paclitaxel/gemcitabine (PAAG) in metastatic pancreatic cancer: a prospective, multicentre, biomolecular exploratory, phase II trial.
    Sha H; Tong F; Ni J; Sun Y; Zhu Y; Qi L; Li X; Li W; Yang Y; Gu Q; Zhang X; Wang X; Zhu C; Chen D; Liu B; Du J
    Signal Transduct Target Ther; 2024 Jun; 9(1):143. PubMed ID: 38844468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and biomarker analysis of second-line nab-paclitaxel plus sintilimab in patients with advanced biliary tract cancer.
    Li X; Zhou N; Yang Y; Lu Z; Gou H
    Cancer Sci; 2024 Jul; 115(7):2371-2383. PubMed ID: 38638055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the efficacy and safety of anlotinib monotherapy or anlotinib plus immune checkpoint inhibitor for advanced small cell lung cancer with brain metastases.
    Xu M; Shao K; Wang Y; Hao Y; Song Z
    Clin Transl Oncol; 2024 Jul; 26(7):1687-1695. PubMed ID: 38363527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The later-line efficacy and safety of immune checkpoint inhibitors plus anlotinib in EGFR-mutant patients with EGFR-TKI-resistant NSCLC: a single-center retrospective study.
    Yin X; Liu X; Ren F; Meng X
    Cancer Immunol Immunother; 2024 May; 73(7):134. PubMed ID: 38758372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anlotinib plus docetaxel vs. docetaxel alone for advanced non-small-cell lung cancer patients who failed first-line treatment: A multicenter, randomized phase II trial.
    Pu X; Xiao Z; Li J; Wu Z; Ma Z; Weng J; Xiao M; Chen Y; Cao Y; Cao P; Wang Q; Xu Y; Li K; Chen B; Xu F; Liu L; Kong Y; Zhang H; Duan H; Wu L
    Lung Cancer; 2024 May; 191():107538. PubMed ID: 38552544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of gemcitabine/nab-paclitaxel combined with anlotinib and PD-1 inhibitors as a first-line treatment for advanced pancreatic cancer.
    Liu H; Pan D; Yao Z; Wang H; Li Y; Qin X; Qu P; Tang J; Han Z
    Int Immunopharmacol; 2024 Sep; 139():112635. PubMed ID: 39002522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II study of pembrolizumab and paclitaxel in patients with relapsed or refractory small-cell lung cancer.
    Kim YJ; Keam B; Ock CY; Song S; Kim M; Kim SH; Kim KH; Kim JS; Kim TM; Kim DW; Lee JS; Heo DS
    Lung Cancer; 2019 Oct; 136():122-128. PubMed ID: 31494530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II study of anlotinib in 45 patients with relapsed small cell lung cancer.
    Wu D; Nie J; Hu W; Dai L; Zhang J; Chen X; Ma X; Tian G; Han J; Han S; Long J; Wang Y; Zhang Z; Fang J
    Int J Cancer; 2020 Dec; 147(12):3453-3460. PubMed ID: 32557583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of multi-target TKI combined with nivolumab in check-point inhibitor-refractory patients with advanced NSCLC: a prospective, single-arm, two-stage study.
    Zhang B; Liu H; Shi C; Gao Z; Zhong R; Gu A; Chu T; Wang H; Xiong L; Zhang W; Zhang X; Yan B; Teng J; Wang W; Bai H; Qiao R; Cheng L; Kuang Y; Zhao R; Zhong H; Han B
    BMC Cancer; 2024 Jun; 24(1):715. PubMed ID: 38862908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anlotinib combined with PD-1 blockade for the treatment of lung cancer: a real-world retrospective study in China.
    Zhang X; Zeng L; Li Y; Xu Q; Yang H; Lizaso A; Mao X; Jin R; Zeng Y; Li Q; Wang J; Li Y; Zhang Y; Yang N
    Cancer Immunol Immunother; 2021 Sep; 70(9):2517-2528. PubMed ID: 33566148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
    Goldman JW; Dvorkin M; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Garassino MC; Voitko O; Poltoratskiy A; Ponce S; Verderame F; Havel L; Bondarenko I; Każarnowicz A; Losonczy G; Conev NV; Armstrong J; Byrne N; Thiyagarajah P; Jiang H; Paz-Ares L;
    Lancet Oncol; 2021 Jan; 22(1):51-65. PubMed ID: 33285097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Anlotinib in EGFR-Positive Patients with Advanced Lung Adenocarcinoma Compared with Chemotherapy: A Retrospective Study.
    Cai C; Shen Q; Shao J; Qu J; Zhou S; Zhou J
    Technol Cancer Res Treat; 2024; 23():15330338241279111. PubMed ID: 39175430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Case report: Sintilimab combined with anlotinib as neoadjuvant chemotherapy for metastatic bone tumor resection in patients with PSC.
    Bao Z; Yu X; Zheng K; Zhai K; Cui H; Xu M
    Front Immunol; 2024; 15():1372279. PubMed ID: 38756778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.